Guangzhou Wondfo Biotech Co., Ltd.
Guangzhou Wondfo Biotech Co., Ltd., headquartered in Guangzhou science city, has been focusing on the R&D, production, sales and service of point-of-care testing (POCT) products and providing customers with professional rapid diagnosis and chronic disease management solutions since founded in 1992. Wondfo now has more than 3000 employees and a wide range of products for the rapid identification of cardiovascular diseases, inflammation, tumor, infectious diseases, drug abuse, pregnancy, and so on, widely sold to 140+ countries and regions.
Find locations served, office locations
- Business Type:
- Industry Type:
- Medical Equipment
- Market Focus:
- Globally (various continents)
This company also provides solutions for other industrial applications.
Please, visit the following links for more info:
Sound Product System
Continuous innovation drives us forward. Wondfo has developed “Nine Technology Platforms”- the immune colloidal gold, immune-fluorescence, electrochemistry, dry biochemistry, chemiluminescence, molecular diagnostics, instrument, pathology, and biological raw material.
Based on the above technology platforms, Wondfo has extended the product lines to the rapid identification of cardiovascular diseases, inflammation, tumor, infectious diseases, drug abuse, pregnancy, etc. Our products are widely used in the rapid diagnosis and effective treatment monitoring of critical and severe diseases, chronic disease management, maternal and children healthcare, blood glucose monitoring, drug detection, alcohol testing, forensic expertise and other fields.
The Flu Series is the star product of Wondfo which keeps brilliant records. It is the only product in China obtaining the registration certificate for antigen detection of H7 subtype avian influenza virus. And it is the only influenza detection product in China with a full range of test menu (H7, FIuA, FIuB, FIuA&B).
In recent years, Wondfo launched a molecular diagnostic technology platform for more accurate diagnosis of influenza diseases, infectious diseases, and tumor concomitant.
In recent years, Wondfo has built a global ' Wondfo Ecosystem' and expanded the global coverage of products, technologies and channels by setting joint innovation bases, joint operation centers, and cross-border mergers and acquisitions.
To integrate global research and innovation resources, Wondfo has established research and development centers in San Diego, and Guangzhou, and introduced more than 530 top-notch researchers at home and abroad.
Besides, Wondfo invested in factories in Asia, South America, Africa and the commonwealth of independent states to build a global manufacturing system that helps reduce the delivery time and cost.
As customer satisfaction to be our priority, Wondfo continues to expand the global service network to more efficiently serve customers all over the world. Wondfo has set up more than 20 subsidiaries worldwide, providing products, solutions, and technical support to customers in more than 140 regions and countries.